Abu dhabi: Abu Dhabi Biobank, a strategic collaboration between the Department of Health - Abu Dhabi (DoH) and global health leader M42, has announced a strategic partnership with BioTwin to expand the deployment of AI-based Virtual Human Twin technology in the UAE. This initiative focuses on early detection, prevention, and precision health. The announcement was made at the BIO International Convention 2026 in San Diego, USA.
According to Emirates News Agency, the partnership combines BioTwin's longitudinal biomarker platform and Virtual Human Twin technology with Abu Dhabi Biobank's ability to connect biological data with genomic, clinical, and AI-driven insights. This collaboration aims to decode complex diseases, accelerate clinical research, and shift healthcare from reactive to proactive, with the initial application targeting multi-cancer screening.
Abu Dhabi has positioned itself as a hub for health innovation, boasting advanced clinical infrastructure, biobanking, genomics, research, and real-world implementation. Through this collaboration, BioTwin and Abu Dhabi Biobank aim to contribute to this ecosystem by advancing a scalable model for early detection and preventive precision health.
Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health - Abu Dhabi, highlighted that Abu Dhabi has developed a global living lab for intelligent life sciences. By integrating population-scale genomics and advanced longitudinal health data with agile regulation, Abu Dhabi has created a future-ready ecosystem aimed at predictive, preventive, and personalized healthcare. This partnership reflects Abu Dhabi's competitive advantage as a premier global hub for life sciences innovation.
Albarah El-Khani, Chief Operating Officer, Integrated Health Solutions, M42, emphasized that the collaboration exemplifies how advanced biobanking infrastructure can facilitate earlier detection, personalized prevention, and therapeutic innovation. Abu Dhabi Biobank offers access to high-quality biological materials, data, governance, and translational pathways, advancing precision medicine through world-class biobanking, data infrastructure, and innovation.
The partnership lays the groundwork for future clinical, operational, and commercial deployment opportunities in Abu Dhabi, beginning with early detection and expanding toward broader applications in preventive health, health optimization, and personalized care.
Louis-Philippe Noel, Founder and Chief Executive Officer of BioTwin, stated that the partnership with Abu Dhabi Biobank is a significant step in BioTwin's mission to make early detection, prevention, and personalized health optimization accessible through Human Virtual Twin technology. Together, they aim to expand a technology platform that supports earlier insight, longitudinal health monitoring, and a proactive model of care. BioTwin's platform incorporates home-based dried blood spot collection, multi-biomarker analysis, and AI-enabled Human Virtual Twin modeling to generate longitudinal insights into individual health trajectories.
